Quick Answer
Metagenomi Therapeutics, Inc. reported Total Revenue of $25.21 million for fiscal year 2025.
Metagenomi Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Revenue | $25.21M -51.8% |
$52.30M +16.8% |
$44.76M | — |
| Revenue (ASC 606) | $25.21M -51.8% |
$52.30M +16.8% |
$44.76M | — |
| Net Income | -$87.87M -12.6% |
-$78.06M -14.4% |
-$68.25M | — |
| Diluted EPS | -$2.36 +0.0% |
-$2.36 +88.2% |
-$20.05 | — |
| Total Assets | $221.10M -31.9% |
$324.60M -11.0% |
$364.84M | — |
| Cash and Equivalents | $41.72M +52.3% |
$27.39M -80.5% |
$140.60M | — |
| Stockholders Equity | $158.60M -32.5% |
$234.86M +273.2% |
-$135.58M -82.2% |
-$74.43M |
| R&D Expense | $94.43M -13.5% |
$109.18M +15.7% |
$94.40M | — |
| Operating Income | -$96.01M -8.0% |
-$88.90M -13.3% |
-$78.49M | — |
| Shares Outstanding | 37.62M +0.5% |
37.42M +999.1% |
3.40M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $8.66M | -24.8% | +1.7% |
| Revenue (ASC 606) | September 30, 2025 | $8.66M | -24.8% | +1.7% |
| Net Income | September 30, 2025 | -$20.39M | -8.6% | -2.4% |
| Diluted EPS | September 30, 2025 | -$0.55 | -7.8% | -1.9% |
| Total Assets | September 30, 2025 | $247.94M | -30.8% | -8.9% |
| Cash and Equivalents | September 30, 2025 | $32.77M | +30.5% | +22.1% |
| Stockholders Equity | September 30, 2025 | $178.45M | -30.2% | -8.9% |
| R&D Expense | September 30, 2025 | $25.28M | -3.7% | +12.3% |
| Operating Income | September 30, 2025 | -$22.84M | -2.0% | -8.8% |
| Shares Outstanding | September 30, 2025 | 37.55M | +0.3% | +0.0% |
- Metagenomi Therapeutics, Inc. reported Total Revenue of $25.21 million for fiscal year 2025.
- Metagenomi Therapeutics, Inc. showed a decrease of -51.8% in Total Revenue compared to the prior fiscal year.
- Metagenomi Therapeutics, Inc. reported Revenue (ASC 606) of $25.21 million for fiscal year 2025.
- Metagenomi Therapeutics, Inc. showed a decrease of -51.8% in Revenue (ASC 606) compared to the prior fiscal year.
- Metagenomi Therapeutics, Inc. reported Net Income of -$87.87 million for fiscal year 2025.
- Metagenomi Therapeutics, Inc. showed a decrease of -12.6% in Net Income compared to the prior fiscal year.
- Metagenomi Therapeutics, Inc. reported Diluted EPS of $2.36 per share (loss) for fiscal year 2025.
- Metagenomi Therapeutics, Inc. showed an increase of +0.0% in Diluted EPS compared to the prior fiscal year.
- Metagenomi Therapeutics, Inc. reported Total Assets of $221.10 million for fiscal year 2025.
- Metagenomi Therapeutics, Inc. showed a decrease of -31.9% in Total Assets compared to the prior fiscal year.
- Metagenomi Therapeutics, Inc. reported Cash and Equivalents of $41.72 million for fiscal year 2025.
- Metagenomi Therapeutics, Inc. showed an increase of +52.3% in Cash and Equivalents compared to the prior fiscal year.
- Metagenomi Therapeutics, Inc. reported Stockholders Equity of $158.60 million for fiscal year 2025.
- Metagenomi Therapeutics, Inc. showed a decrease of -32.5% in Stockholders Equity compared to the prior fiscal year.
- Metagenomi Therapeutics, Inc. reported R&D Expense of $94.43 million for fiscal year 2025.
- Metagenomi Therapeutics, Inc. showed a decrease of -13.5% in R&D Expense compared to the prior fiscal year.
- Metagenomi Therapeutics, Inc. reported Operating Income of -$96.01 million for fiscal year 2025.
- Metagenomi Therapeutics, Inc. showed a decrease of -8.0% in Operating Income compared to the prior fiscal year.
- Metagenomi Therapeutics, Inc. reported Shares Outstanding of 37.62 million shares for fiscal year 2025.
- Metagenomi Therapeutics, Inc. showed an increase of +0.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: